Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 15, 2026, 9:05 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 409–432 of 1,936 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Chronic Renal Disease Clear all
Completed Not applicable Interventional Results available

Project to Improve Communication About Serious Illness - Pilot Study

NCT03746392
View directory record Official record
Conditions
Malignant Neoplasm, Leukemia, Lymphocytic, Chronic, B-Cell, Lung Disease Chronic, Congestive Heart Failure, Liver Failures, Chronic, Renal Insufficiency, Chronic, Dementia, Diabetes Complications, Peripheral Vascular Disease, Frail Elderly
Interventions
Jumpstart Intervention
Behavioral
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
2
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Aug 22, 2025 · Synced Oct 15, 2026, 9:05 AM EDT
Terminated Phase 4 Interventional

Effect of Growth Hormone on Leptin, Cytokines and Body Composition of Children With Growth Failure Due to Chronic Kidney Disease

NCT00194961
View directory record Official record
Conditions
Chronic Kidney Disease
Interventions
Recombinant Human Growth Hormone
Drug
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
6 Months to 18 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2007
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 25, 2008 · Synced Oct 15, 2026, 9:05 AM EDT
Not yet recruiting Phase 1 Interventional

Study of ChoironeX GalKO Porcine Thymokidney Xenotransplantation in End-Stage Renal Disease

NCT07696962
View directory record Official record
Conditions
End Stage Renal Disease
Interventions
ChoironeX GalKO Porcine Thymokidney
Biological
Lead sponsor
Xeno Holdings (US), LLC dba ChoironeX
Industry
Eligibility
18 Years to 70 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
2
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 2, 2026 · Synced Oct 15, 2026, 9:05 AM EDT
Not listed Not applicable Interventional

Hemodialysis in the Elderly (70yrs & Older)

NCT03065972
View directory record Official record
Conditions
Kidney Disease, Kidney Failure, Chronic Kidney Disease
Interventions
Surgical fistula creation from patient's anatomy, Surgical Graft implant
Procedure · Device
Lead sponsor
E. Peden, MD
Other
Eligibility
70 Years and older
Enrollment
270 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2025
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 14, 2023 · Synced Oct 15, 2026, 9:05 AM EDT
Completed Phase 2 Interventional Results available

A Study to Evaluate TOUR006 in Patients With Chronic Kidney Disease and Elevated Hs-CRP

NCT06362759
View directory record Official record
Conditions
Chronic Kidney Diseases, Chronic Kidney Insufficiency, Chronic Renal Diseases, Chronic Renal Insufficiency, Kidney Insufficiency, Chronic, C-Reactive Protein, High Sensitivity C-Reactive Protein, Hs-CRP, hsCRP
Interventions
TOUR006 - 50 MG, TOUR006 - 25 MG, TOUR006 - 15 MG, Placebo
Drug · Other
Lead sponsor
Tourmaline Bio, Inc., a Novartis Company
Industry
Eligibility
18 Years and older
Enrollment
143 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
38
States / cities
Birmingham, Alabama • Huntsville, Alabama • Phoenix, Arizona + 32 more
Source: ClinicalTrials.gov public record
Updated Aug 11, 2026 · Synced Oct 15, 2026, 9:05 AM EDT
Completed Phase 2 Interventional

A Research Study to See if Kidney Damage in People With Chronic Kidney Disease and Type 2 Diabetes Living With Overweight or Obesity Can be Reduced by CagriSema Compared to Semaglutide, Cagrilintide and Placebo

NCT06131372
View directory record Official record
Conditions
Chronic Kidney Disease, Type 2 Diabetes, Obesity
Interventions
Cagrilintide, Semaglutide, Placebo
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
626 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
25
States / cities
Concord, California • Fresno, California • Palm Springs, California + 22 more
Source: ClinicalTrials.gov public record
Updated Sep 24, 2026 · Synced Oct 15, 2026, 9:05 AM EDT
Recruiting Not applicable Interventional

WIN Ratio Analysis to Determine a Strategy of Non- Invasive SUpport for Respiratory Failure in the EmeRgency Department

NCT07558265
View directory record Official record
Conditions
Acute Hypoxic Respiratory Failure, Acute Respiratory Distress Syndrome (ARDS)
Interventions
Non-Invasive Positive Pressure Ventilation, High Flow Nasal Oxygen
Device
Lead sponsor
Ohio State University
Other
Eligibility
18 Years and older
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
6
States / cities
Tucson, Arizona • Ann Arbor, Michigan • Columbus, Ohio + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 1, 2026 · Synced Oct 15, 2026, 9:05 AM EDT
Completed Phase 4 Interventional

Iron Dosing Pilot Study Using Model Predictive Control

NCT03633656
View directory record Official record
Conditions
Renal Insufficiency, Chronic, Anemia, Iron Deficiency, Anemia of Chronic Kidney Disease
Interventions
Model predictive control, Model Predictive Control of Iron Dosing
Device
Lead sponsor
University of Louisville
Other
Eligibility
18 Years to 80 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
1
States / cities
Louisville, Kentucky
Source: ClinicalTrials.gov public record
Updated Apr 13, 2021 · Synced Oct 15, 2026, 9:05 AM EDT
Completed No phase listed Observational

Comparative Outcome Measures of Patients Receiving Acute Renal ThErapy Study

NCT04912024
View directory record Official record
Conditions
End Stage Kidney Disease, End Stage Renal Disease, Acute Kidney Injury
Interventions
Intermittent Renal Replacement Therapy using the Tablo Hemodialysis System, Intermittent Renal Replacement Therapy using Conventional Hemodialysis Systems
Device
Lead sponsor
Outset Medical
Industry
Eligibility
18 Years and older
Enrollment
458 participants
Timeline
2021 – 2022
U.S. locations
2
States / cities
Orlando, Florida • Fort Worth, Texas
Source: ClinicalTrials.gov public record
Updated Aug 12, 2022 · Synced Oct 15, 2026, 9:05 AM EDT
Completed Phase 2Phase 3 Interventional

Myfortic vs. Cellcept in Kidney Transplant Recipients

NCT00533624
View directory record Official record
Conditions
End Stage Renal Disease
Interventions
Mycophenolate Sodium Delayed Release Tablets, Mycophenolate Mofetil
Drug
Lead sponsor
University of Miami
Other
Eligibility
18 Years to 75 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Sep 28, 2023 · Synced Oct 15, 2026, 9:05 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Transformative Research in Diabetic Nephropathy 2.0

NCT07444203
View directory record Official record
Conditions
Diabetic Nephropathies, Kidney Diseases, Renal Insufficiency, Chronic, Diabetes Mellitus, Type 2
Interventions
Sodium-glucose cotransporter 2 inhibitors (SGLT2i), Renin-angiotensin-aldosterone system blockade, Glucagon-like peptide-1 receptor agonists (GLP 1 RA), Mineralocorticoid Receptor Antagonists(MRAs)
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2028
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 2, 2026 · Synced Oct 15, 2026, 9:05 AM EDT
Completed Phase 2Phase 3 Interventional Results available

Folic Acid for Vascular Outcome Reduction In Transplantation (FAVORIT)

NCT00064753
View directory record Official record
Conditions
Chronic Kidney Disease, Cardiovascular Disease, Death
Interventions
High Dose Multivitamin, Low Dose Multivitamin
Drug · Device
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
35 Years to 75 Years
Enrollment
4,110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2011
U.S. locations
27
States / cities
Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 22 more
Source: ClinicalTrials.gov public record
Updated Oct 18, 2017 · Synced Oct 15, 2026, 9:05 AM EDT
Completed Phase 2 Interventional

The Effects of Nutrition Supplementation and Resistance Exercise During Hemodialysis

NCT00179179
View directory record Official record
Conditions
End Stage Renal Disease
Interventions
nutritional supplementation, exercise
Drug · Behavioral
Lead sponsor
Vanderbilt University
Other
Eligibility
18 Years to 75 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jul 9, 2009 · Synced Oct 15, 2026, 9:05 AM EDT
Withdrawn No phase listed Observational

Inflammation in Peritoneal Dialysis Patients: Effect of Obesity

NCT01691196
View directory record Official record
Conditions
End-Stage Renal Disease, Renal Disease, End-Stage, Renal Failure, End-Stage, Obesity
Interventions
Not listed
Lead sponsor
University of Illinois at Chicago
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Oct 29, 2019 · Synced Oct 15, 2026, 9:05 AM EDT
Withdrawn Not applicable Interventional

Effects of Vitamin D on Renal Blood Flow, Proteinuria and Inflammation in Patients With Chronic Kidney Disease

NCT01426724
View directory record Official record
Conditions
Chronic Kidney Disease, Secondary Hyperparathyroidism
Interventions
Contrast Enhanced Ultrasonography
Drug
Lead sponsor
University of Virginia
Other
Eligibility
18 Years to 75 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated May 21, 2014 · Synced Oct 15, 2026, 9:05 AM EDT
Withdrawn Phase 4 Interventional

Direct-acting Antiviral Therapy to Prevent HCV Infection for HCV Positive Donor to HCV Negative Recipient Kidney Transplant

NCT03093740
View directory record Official record
Conditions
Renal Failure Chronic, Hepatitis C
Interventions
Zepatier, Zepatier plus Sofosbuvir
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
40 Years to 70 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 20, 2018 · Synced Oct 15, 2026, 9:05 AM EDT
Recruiting Phase 3 Interventional

A Study to Evaluate the Safety (Compared to Iron Sucrose), Efficacy and Pharmacokinetics of Ferumoxytol for the Treatment of Iron Deficiency Anemia (IDA) in Pediatric Subjects With Chronic Kidney Disease (CKD)

NCT03619850
View directory record Official record
Conditions
Chronic Kidney Disease; Iron Deficiency Anemia
Interventions
Ferumoxytol, Iron sucrose
Drug
Lead sponsor
AMAG Pharmaceuticals, Inc.
Industry
Eligibility
2 Years to 17 Years
Enrollment
129 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
8
States / cities
Hollywood, Florida • Detroit, Michigan • Kansas City, Missouri + 5 more
Source: ClinicalTrials.gov public record
Updated Apr 17, 2026 · Synced Oct 15, 2026, 9:05 AM EDT
Completed Phase 3 Interventional Results available

Ferric Carboxymaltose (FCM) Assessment in Subjects With Iron Deficiency Anaemia and Non-dialysis-dependent Chronic Kidney Disease (NDD-CKD)

NCT00994318
View directory record Official record
Conditions
Iron Deficiency Anaemia, Chronic Kidney Disease
Interventions
FCM (Ferric carboxymaltose) high ferritin target, FCM (Ferric carboxymaltose) low ferritin target, Oral Iron (Ferrous sulphate)
Drug
Lead sponsor
Vifor Pharma
Industry
Eligibility
18 Years and older
Enrollment
626 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
1
States / cities
Wilmington, North Carolina
Source: ClinicalTrials.gov public record
Updated May 20, 2014 · Synced Oct 15, 2026, 9:05 AM EDT
Recruiting Not applicable Interventional

Enhancing Physical Function in Older Adults With Chronic Kidney Disease

NCT06738394
View directory record Official record
Conditions
Chronic Kidney Diseases
Interventions
High-Velocity Resistance Training, Attention
Behavioral
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
65 Years to 100 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 26, 2026 · Synced Oct 15, 2026, 9:05 AM EDT
Completed Phase 1 Interventional

Open-Label Safety, Tolerability, PK Study of IV CXA-10 Emulsion in Subjects in Chronic Kidney Injury

NCT02248051
View directory record Official record
Conditions
Acute Kidney Injury (Nontraumatic)
Interventions
CXA-10
Drug
Lead sponsor
Complexa, Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
2
States / cities
Anaheim, California • Kalamazoo, Michigan
Source: ClinicalTrials.gov public record
Updated Feb 1, 2018 · Synced Oct 15, 2026, 9:05 AM EDT
Completed Phase 4 Interventional Results available

Safety and Cardiovascular Efficacy of Hydralazine and Isosorbide Dinitrate in Dialysis-Dependent ESRD

NCT02228408
View directory record Official record
Conditions
Chronic Hemodialysis (ESRD)
Interventions
Hydralazine/Isorsorbide Dinitrate, Placebo
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years to 85 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 27, 2021 · Synced Oct 15, 2026, 9:05 AM EDT
Completed Phase 2 Interventional Results available

20-Week Repeat Oral Dose Study of AKB-6548 in Participants With Chronic Kidney Disease and Anemia

NCT01906489
View directory record Official record
Conditions
Anemia, Chronic Kidney Disease
Interventions
AKB-6548, Placebo
Drug
Lead sponsor
Akebia Therapeutics
Industry
Eligibility
18 Years to 82 Years
Enrollment
210 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
47
States / cities
Glendale, Arizona • Tucson, Arizona • Azusa, California + 44 more
Source: ClinicalTrials.gov public record
Updated Jul 21, 2022 · Synced Oct 15, 2026, 9:05 AM EDT
Completed Phase 2 Interventional Results available

Study to Assess the Safety and Pharmacokinetics of AKB-6548 in Participants With Chronic Kidney Disease (CKD), Stages 3 and 4

NCT04707573
View directory record Official record
Conditions
Chronic Kidney Disease
Interventions
Vadadustat
Drug
Lead sponsor
Akebia Therapeutics
Industry
Eligibility
18 Years to 79 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
2
States / cities
Saint Paul, Minnesota • Knoxville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jun 28, 2022 · Synced Oct 15, 2026, 9:05 AM EDT
Completed Phase 2 Interventional Results available

Provision of Antioxidant Therapy in Hemodialysis (PATH) Study

NCT00237718
View directory record Official record
Conditions
End-stage Renal Disease
Interventions
Alpha, gamma, beta, and delta (mixed) tocopherols, Alpha lipoic acid, Placebo
Drug
Lead sponsor
Vanderbilt University
Other
Eligibility
18 Years and older
Enrollment
385 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jan 11, 2012 · Synced Oct 15, 2026, 9:05 AM EDT